Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2014

View Archived Issues

Identification of novel antigens for multicomponent malaria vaccines

Aldea Pharmaceuticals closes Series B financing

Reprogramming of porcine ventricular cardiomyocytes to generate a biological pacemaker

Genome-wide copy DNA screening uncovers a novel regulator of brown fat adaptive thermogenesis

Novel series of aldosterone synthase inhibitors discovered at Merck & Co.

NEOMED Institute presents new P2X3 receptor antagonists

New PDE4B inhibitors disclosed by Gruenenthal

Telik receives NCI contract to develop antibody-based PET imaging agent

FDA approves Zorvolex for management of osteoarthritis pain

Novel 5-HT6 receptor agonists show significant efficacy in animal models of cognition

NEOMED Institute receives Canadian government funding

MediciNova cleared to begin clinical study of ibudilast in ALS

Cilag acquires Covagen

Alexion begins trial of eculizumab to prevent delayed graft function after kidney transplantation

La Jolla Pharmaceutical initiates phase I/II trial of LJPC-501 in hepatorenal syndrome

Alkermes files NDA for depot formulation of aripiprazole lauroxil for schizophrenia

Cancer Genetics enters collaboration to discover diffuse large B-cell lymphoma markers

Findings from preclinical study of DepoVax-formulated vaccine for Ebola

NFkB decoy oligonucleotide moves to phase III study in atopic dermatitis

Roche to acquire InterMune

FDA approves Triumeq for HIV

OncoSynergy plans study of anticancer MAb in Ebola virus infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...